These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27112533)

  • 1. Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population.
    Modi A; Sajjan S; Michael Lewiecki E; Harris ST; Papadopoulos Weaver J
    Clin Ther; 2016 May; 38(5):1074-80. PubMed ID: 27112533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
    Modi A; Siris ES; Steve Fan CP; Sajjan S
    Clin Ther; 2015 Jun; 37(6):1228-34. PubMed ID: 25866298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women.
    Yu J; Goldshtein I; Shalev V; Chodick G; Ish-Shalom S; Sharon O; Modi A
    Int J Clin Pract; 2015 Sep; 69(9):1007-14. PubMed ID: 26278464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of gastrointestinal events with osteoporosis treatment initiation and treatment compliance in Germany: An observational study.
    Modi A; Fan CS; Tang J; Weaver JP; Sajjan S
    Bone Rep; 2016 Dec; 5():208-213. PubMed ID: 28580388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between gastrointestinal events and compliance with osteoporosis therapy.
    Siris ES; Fan CS; Yang X; Sajjan S; Sen SS; Modi A
    Bone Rep; 2016 Jun; 4():5-10. PubMed ID: 28326336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
    Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
    Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between gastrointestinal events and persistence with osteoporosis therapy: analysis of administrative claims of a U.S. managed care population.
    Modi A; Siris S; Yang X; Fan CP; Sajjan S
    J Manag Care Spec Pharm; 2015 Jun; 21(6):499-506. PubMed ID: 26011551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage.
    Siris ES; Yu J; Bognar K; DeKoven M; Shrestha A; Romley JA; Modi A
    Clin Interv Aging; 2015; 10():1813-24. PubMed ID: 26604724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between gastrointestinal events and osteoporosis treatment initiation in women diagnosed with osteoporosis in France: a retrospective analysis.
    Cortet B; Modi A; Tang J; Fan CP; Sajjan S; Weaver JP
    BMC Musculoskelet Disord; 2016 Apr; 17():195. PubMed ID: 27139225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.
    Cramer JA; Lynch NO; Gaudin AF; Walker M; Cowell W
    Clin Ther; 2006 Oct; 28(10):1686-94. PubMed ID: 17157124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Gastrointestinal Events and Health Care Resource Utilization Among Patients with Osteoporosis: Analysis of a U.S. Managed Care Population.
    Modi A; Gold DT; Yang X; Fan CP; Sajjan SG
    J Manag Care Spec Pharm; 2015 Sep; 21(9):811-21. PubMed ID: 26308228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
    Modi A; Siris ES; Tang J; Sen S
    Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost and consequences of noncompliance to oral bisphosphonate treatment.
    Eisenberg DF; Placzek H; Gu T; Krishna A; Tulsi BB
    J Manag Care Spec Pharm; 2015 Jan; 21(1):56-65. PubMed ID: 25562773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal events and association with initiation of treatment for osteoporosis.
    Modi A; Siris ES; Tang J; Sajjan S; Sen SS
    Clinicoecon Outcomes Res; 2015; 7():603-13. PubMed ID: 26648746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
    Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
    Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
    Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
    Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
    J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.